Citius Pharmaceuticals, Inc. (CTXR)
CTXR Stock Price Chart
Explore Citius Pharmaceuticals, Inc. interactive price chart. Choose custom timeframes to analyze CTXR price movements and trends.
CTXR Company Profile
Discover essential business fundamentals and corporate details for Citius Pharmaceuticals, Inc. (CTXR) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
2 Oct 2014
Employees
23.00
Website
https://www.citiuspharma.comCEO
Leonard L. Mazur
Description
Citius Pharmaceuticals, Inc. operates as a specialized pharmaceutical firm concentrating on the development and market introduction of critical care products. Its efforts are particularly directed towards anti-infective treatments supporting cancer care, various prescription medications, and pioneering mesenchymal stem cell therapies. The company is actively advancing five unique products within its pipeline: Mino-Lok: An antibiotic lock solution designed to combat catheter-related bloodstream infections by salvaging the infected central venous catheter. Mino-Wrap: A novel liquifying gel-based wrap aimed at minimizing infections associated with tissue expanders following breast reconstructive procedures. Halo-Lido: A topical formulation that blends a corticosteroid with lidocaine, intended to deliver both anti-inflammatory and numbing relief to individuals suffering from hemorrhoids. NoveCite: A mesenchymal stem cell therapy currently under development for treating acute respiratory distress syndrome (ARDS). I/ONTAK: An engineered fusion protein, combining IL-2 and diphtheria toxin, purposed for the treatment of patients experiencing persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
CTXR Financial Timeline
Browse a chronological timeline of Citius Pharmaceuticals, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 Aug 2026
EPS estimate is -$0.36, while revenue estimate is $5.46m.
Earnings released on 15 May 2026
EPS came in at -$0.95 falling short of the estimated -$0.28 by -238.38%, while revenue for the quarter reached $1.67m , missing expectations by -83.70%.
Earnings released on 13 Feb 2026
EPS came in at -$0.38 falling short of the estimated $0.43 by -188.39%, while revenue for the quarter reached $3.94m , missing expectations by -78.10%.
Earnings released on 25 Dec 2025
EPS came in at -$0.44 falling short of the estimated -$0.24 by -83.55%, while revenue for the quarter reached $3.94m .
Earnings released on 12 Aug 2025
EPS came in at -$0.80 falling short of the estimated -$0.24 by -233.33%.
Earnings released on 14 May 2025
EPS came in at -$1.27 falling short of the estimated -$1.08 by -17.59%.
Earnings released on 14 Feb 2025
EPS came in at -$1.30 falling short of the estimated -$1.25 by -4.00%.
Earnings released on 3 Jan 2025
EPS came in at -$1.75 falling short of the estimated -$0.04 by -4.28k%, while revenue for the quarter reached $155.93k , missing expectations by -97.79%.
Earnings released on 12 Aug 2024
EPS came in at -$1.50 falling short of the estimated -$1.25 by -20.00%.
Earnings released on 14 May 2024
EPS came in at -$1.25 surpassing the estimated -$1.50 by +16.67%.
Earnings released on 14 Feb 2024
EPS came in at -$1.50 falling short of the estimated $3.25 by -146.15%.
Earnings released on 29 Dec 2023
EPS came in at -$1.75 falling short of the estimated -$0.44 by -300.00%.
Earnings released on 14 Aug 2023
EPS came in at -$1.50 matching the estimated -$1.50.
Earnings released on 12 May 2023
EPS came in at -$1.75 falling short of the estimated -$1.00 by -75.00%.
Earnings released on 10 Feb 2023
EPS came in at -$1.00 .
Earnings released on 22 Dec 2022
EPS came in at -$1.25 falling short of the estimated -$1.00 by -25.00%.
Earnings released on 11 Aug 2022
EPS came in at -$1.50 falling short of the estimated -$1.25 by -20.00%.
Earnings released on 12 May 2022
EPS came in at -$1.25 surpassing the estimated -$2.00 by +37.50%.
Earnings released on 10 Feb 2022
EPS came in at -$1.50 matching the estimated -$1.50.
Earnings released on 15 Dec 2021
EPS came in at -$0.75 matching the estimated -$0.75.
Earnings released on 12 Aug 2021
EPS came in at -$1.25 matching the estimated -$1.25.
CTXR Stock Performance
Access detailed CTXR performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
